NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience

antibody

SERPINB2 Monoclonal Antibody (OTI1G3)

MA5-25775

100 uL

US 514.00

monoclonal

mouse

nonconjugated

OTI1G3

The same clone is also sold as:

• Novus Biologicals: NBP2-01492, NBP2-74131
• OriGene: CF503926, TA503926BM, TA503926, TA503926S, TA503926AM

western blot, immunohistochemistry, flow cytometry, immunohistochemistry - paraffin section

SERPINB2 Monoclonal Antibody (OTI1G3)

MA5-25775

100 uL

US 514.00

Monoclonal

Affinity Chromatography

Mouse

Human

Flow Cytometry: 1:100, Immunohistochemistry (Paraffin): 1:150, Western Blot: 1:500

Human

OTI1G3

IgG1

-20 C, Avoid Freeze/Thaw Cycles

PAI-2 is an inhibitory serpin expressed mainly in keratinocytes, activated monocytes, and placental trophoblasts. It exists predominantly as a 47 kDa, nonglycosylated, intracellular protein, which can be induced to be secreted as 60 kDa glycoprotein. The glycosylated and unglycosylated forms of PAI-2 are equally effective as inhibitors of urokinase-type plasminogen activator (uPA), the only established physiological target of this serpin. PAI-2 has a unique ability to form dormant polymers spontaneously and reversibly under physiological conditions. The physiological relevance of this property, which is neither a consequence of any mutation in the PAI-2 gene nor associated with any known disorder, is still unclear. However, it appears that the formation of intracellular, dormant polymers may be important for the controlled release of the inhibitor from PAI-2 producing cells. Plasma levels of PAI-2 are usually low or undetectable, except during pregnancy and in some forms of monocytic leukemia. Secretion of PAI-2 from the placenta normally occurs during the third trimester of pregnancy, and accounts for the dramatic increase in PAI-2 levels (up to 250 ng/ml), which are maintained at these levels until postpartum, and then rapidly decline. In addition to its vital role in protecting the placenta from degradation by uPA and/or uPA-activated proteases, PAI-2 has been shown to be essential for the prevention of metastatic spread of neck, lung and breast cancers. The beneficial effect of PAI-2 seen in these studies is presumed to stem from its ability to inhibit uPA-dependent cell dissemination. PAI-2 has also been reported to inhibit keratinocyte proliferation, and to participate in the innate immune response during viral infection.

Full length human recombinant protein of SERPINB2 produced in HEK293T cell

Liquid

Flow Cytometry: 1:100, Immunohistochemistry (Paraffin): 1:150, Western Blot: 1:500

HsT1201; Monocyte Arg-serpin; ovalbumin; PAI; Pai2; PAI-2; Pai2a; Placental plasminogen activator inhibitor; Planh2; Plasminogen activator inhibitor 2; plasminogen activator inhibitor 2 type A; Plasminogen activator inhibitor 2, macrophage; plasminogen activator inhibitor, type II; plasminogen activator inhibitor, type II (arginine-serpin); serine (or cysteine) peptidase inhibitor, clade B, member 2; serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 2; serine (or cysteine) proteinase inhibitor, clade B, member 2; serpin B2; serpin family B member 2; serpin peptidase inhibitor, clade B (ovalbumin), member 2; SERPINB2; Urokinase inhibitor